Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $56.98, but opened at $59.56. Zealand Pharma A/S shares last traded at $59.56, with a volume of 125 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, July 1st. Barclays raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday. One research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Zealand Pharma A/S currently has a consensus rating of "Strong Buy".

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The company has a 50 day simple moving average of $64.15 and a 200-day simple moving average of $79.23. The stock has a market capitalization of $4.09 billion, a P/E ratio of -23.12 and a beta of 0.68.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. The business had revenue of $1.14 million for the quarter, compared to analysts' expectations of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. On average, equities analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.